INTRODUCTION
Monofocal intraocular lenses (IOLs) are traditionally used to replace the opacified natural lens that is removed during cataract surgery. Limitations of such IOLs, primarily a limited depth of focus providing clear vision either at distance or near, and dependence on reading spectacles for clear vision at all other viewing distances, have long been recognized [1, 2] .
Refractive multifocal IOLs were developed to provide clear, spectacle-free vision over a wider range of distances. These IOLs distribute the incoming light to hit multiple focal points on the lens, consequently, creating multiple simultaneous retinal images. A disadvantage is that only one of these images is in focus at any given time. All other out-of-focus images may be detected as disturbances, including glare, halos, and poor contrast sensitivity [3] . In addition, some existing multifocal IOL designs distribute more light to the distance focus, compromising near visual acuity [4, 5] .
In response to these limitations, diffractive multifocal IOL models have been developed.
Unlike refractive multifocal IOLs, which have a series of focal zones for incoming light, diffractive IOLs have just two separate focal points: one for distance and one for near vision.
Because of this design, diffractive multifocal IOLs may provide clear, spectacle-free distance and near vision, while avoiding the poor visual quality that typically arises from multiple foci [1] .
We conducted this study to assess objective and subjective visual outcomes of patients implanted with the Acriva UD Reviol MFB 625 (VSY Biotechnology, Istanbul, Turkey), a hydrophobic, diffractive multifocal IOL.
METHODS
This multicenter, prospective clinical study involved patients scheduled to undergo cataract surgery between October 2010 and July 2011 at seven study sites. The study was conducted in accordance with the ethical standards stated in the Declaration of Helsinki, and all patients provided informed consents prior to the study. The study was approved by the Ethics Committee of the coordinator center which was Uludag University Medical Faculty, Bursa, Turkey.
All patients underwent bilateral phacoemulsification followed by implantation of a foldable, hydrophobic acrylic diffractive multifocal IOL (Acriva UD Reviol MFB 625; VSY Biotechnology, Istanbul, Turkey).
Acriva UD Reviol MFB 625 (Fig. 1) 
RESULTS
Two hundred eyes of 100 patients (53% male), with a mean age of 62.60 ± 9.32 years, were included in this study. All patients were followed up for a period of at least 12 months.
Of the patients, 97% had visual loss in both eyes. The hardness of the cataractous lens was 2.7 ± 0.8, the axial length was 23.2 ± 0.9 mm, and the power of the IOL implanted was 21.3 ± 2.4 diopters. The visual characteristics of the patients at baseline and at 1, 6, and 12 months of surgery, are presented in Table 1 . The percentages of the patients within 0.5 D of manifest spherical equivalent and 0.5 D of cylinder are presented in Table 2 .
Monocular and binocular visual acuities at all distances showed improvement at postoperative 12 months compared to preoperative measurements (P\0.001, for all). The binocular UCDVA was 0.84 ± 0.21 dec, UCIVA was J 1.14 ± 0.39 dec, and UCNVA was J 1.04 ± 0.19 at postoperative 12 months. Monocular and binocular visual acuities recorded preoperatively and at 1, 6, and 12 months of surgery are presented in Table 3 .
Distribution of monocular and binocular visual acuities based on Snellen chart according to age groups is presented in Table 4 .
Binocular contrast sensitivity results with and without glare at 3, 6, 12, and 18 cycles per degree (cpd) at 1, 6, and 12 months of surgery are presented in Table 5 . Normal reading levels of contrast sensitivity were defined as 0-8 cpd.
Binocular distance contrast sensitivity values (with and without glare) for each spatial frequency showed significant improvement at postoperative 12 months compared with postoperative 1 month, except for 3 cpd (without glare) and 18 cpd (with glare).
There was no significant change in monocular and binocular near contrast sensitivity (VAS) values with time. Monocular 
\0.001
Values [6] that near and distance visual acuities achieved with a diffractive multifocal IOL were found The findings of the current study suggest that the Acriva UD Reviol MFB 625 IOL improves patient visual acuity at all distances, near and distance contrast sensitivity, quality of life and patient satisfaction by 12 months after implantation.
The Acriva UD Reviol MFB 625 has a near addition of ?3.75 D with a light distribution of 60% for distance focus and 40% for near focus.
The current study findings showed that patients implanted with this IOL experienced a gradual improvement in mean monocular and binocular visual acuities at each successive visit. The level of visual acuity achieved in the current study is noticeably better than that reported by similar studies involving refractive multifocal IOLs. For example, in a study by Steinert et al. [4] 80.0% of patients achieved a UCNVA above J3 and in the current study, 82.8% of the patients achieved a UCNVA of J1 or better by the twelfth postoperative month. In a study by Can et al. [7] , in which visual outcomes with two diffractive multifocal IOLs (the Acriva UD Reviol MFM 611 and Acri Lisa 366D) were compared, distance and near visual acuities were found to be similar with both [7] study, the clinical results of 2 diffractive multifocal IOLs, Acriva Reviol MFM 611 and Acri.Lisa 366D, were compared and stated that although differences in mesopic contrast sensitivity with glare and without glare between the 2 IOLs were not statistically significant, the results were better with the Acriva Reviol MFM 611 IOL. Both distance and near contrast sensitivity were assessed in a multifocal versus monofocal IOL study by Montés-Micó et al. [9] . Distance contrast sensitivity was better with a monofocal than multifocal IOL during the first 3 months after surgery.
However, contrast sensitivity significantly improved, especially after the third month, reaching the same level as that In the present study, contrast sensitivity values, with and without glare, were all within the normal limits during the follow-up period. In many other studies including diffractive and refractive multifocal IOLs, similar results were reported [8, [11] [12] [13] . Further studies with longer follow-up are required to determine the longterm stability of these results. [17] . They concluded that in most cases, Nd:YAG laser capsulotomy in patients with multifocal IOL's did not change the refraction. In the present study, no complications were observed after Nd:YAG laser posterior capsulotomy and this procedure did not change the refraction. 
